Johnson & Johnson history is often told through familiar consumer products: Band-Aid bandages, Johnson’s Baby Powder, Tylenol, Neutrogena, Motrin, and Acuvue contact lenses. But the company’s larger story is less about any single product than about a business model that kept expanding across medicine, consumer health, pharmaceuticals, diagnostics, and medical devices.
That breadth became the defining feature of J&J. By the end of the 20th century, the company had grown from a New Brunswick, New Jersey, maker of surgical dressings into one of the biggest healthcare companies in the world, with operations spread across consumer products, prescription drugs, professional medical equipment, diagnostics, and surgical technology.
The company’s rise also came with recurring tensions: decentralization versus efficiency, public trust versus product risk, consumer branding versus clinical credibility, and social responsibility versus the pressure to keep growing. Few companies have had as many household-name products. Few have also had to manage so many reputational tests across such different corners of healthcare.
From Surgical Dressings to a Healthcare Business
Johnson & Johnson traces its roots to the late 19th century, when antiseptic surgery was reshaping medicine. Joseph Lister’s work on germs and surgical infection created a commercial opening for companies that could produce cleaner, more reliable medical supplies. Johnson & Johnson’s own corporate history places Robert Wood Johnson and his brothers, James Wood Johnson and Edward Mead Johnson, at the center of that early push.
The brothers began producing surgical dressings in New Brunswick in 1886. The operation started small, reportedly with a modest staff in a former wallpaper factory, and focused on a practical problem: hospitals and surgeons needed sterile, ready-to-use materials at a time when infection after surgery was a major concern.
The company incorporated in 1887 and found demand for products tied to antiseptic surgical practice. Early Johnson & Johnson products included medicinal plasters and cotton-and-gauze dressings. The company also moved toward sterilized bandages, using heat, steam, and pressure as it refined its manufacturing process.
That early period mattered because it set the pattern for much of what followed. J&J did not begin as a cosmetics company or a drug developer. It began as a supplier to professional medicine, then gradually learned how to translate medical credibility into consumer trust.
Fred B. Kilmer, who became the company’s scientific director in the late 1880s, helped push that strategy forward. Kilmer wrote and edited material aimed at doctors, pharmacists, and the public, promoting antiseptic methods while also building confidence in J&J’s products. The approach was part education, part marketing, and part category creation.
By the 1890s, Johnson & Johnson was expanding beyond surgical dressings. Johnson’s Baby Powder, introduced in 1893, gave the company an early foothold in baby care. The company’s growing catalog suggested a broader ambition: use medical manufacturing know-how to sell both to hospitals and to households.
The Products That Made J&J Familiar
The early 20th century brought some of the products that would turn Johnson & Johnson into a consumer name. Band-Aid brand adhesive bandages arrived in 1921, becoming one of the company’s most recognizable inventions. Johnson’s Baby Cream followed in the same era, building on the baby-care business that had begun with powder decades earlier.
The company also moved into feminine hygiene. Modess sanitary napkins debuted in 1927, and later products such as Carefree, Stayfree, and o.b. would become important parts of J&J’s consumer portfolio. The company was not simply adding adjacent products; it was building a presence in everyday health routines, from wound care to infant care to personal care.
International expansion started early. Johnson & Johnson established an affiliate in Canada in 1919 and expanded to Great Britain in the 1920s. That overseas push would become an essential part of the company’s long-term structure, especially as healthcare markets outside the United States became increasingly important.
The company also made acquisitions to support its manufacturing needs. In 1916, J&J bought Chicopee Manufacturing Corporation, helping secure textile materials for its growing surgical and hygiene businesses.
A simplified timeline shows how quickly the company moved from a focused surgical-supply manufacturer to a more diversified healthcare business:
| Year | Milestone | Why it mattered |
|---|---|---|
| 1886 | Johnson & Johnson begins producing surgical dressings | Establishes the company around antiseptic medical supplies |
| 1887 | The company incorporates | Formalizes the business as demand for sterile products grows |
| 1893 | Johnson’s Baby Powder debuts | Marks an early move into consumer health and baby care |
| 1919 | First international affiliate opens in Canada | Begins the company’s long overseas expansion |
| 1921 | Band-Aid brand adhesive bandages launch | Creates one of J&J’s most enduring consumer brands |
| 1927 | Modess sanitary napkins debut | Expands J&J’s role in personal care |
The consumer products were important because they gave Johnson & Johnson a direct relationship with families, not just hospitals and doctors. That relationship would later become a major asset when the company entered more competitive over-the-counter drug categories.
The General and the Decentralized Company
Robert Wood Johnson II, often known as “the General,” became one of the most important figures in Johnson & Johnson history. He joined the business young, moved through the ranks, and became president in 1932. During World War II, he served as a brigadier general and as vice chairman of the War Production Board.
Johnson pushed a decentralized model that gave J&J divisions and affiliates significant autonomy. That structure let specialized units make decisions close to their markets, whether they were working in sutures, sanitary products, pharmaceuticals, or surgical supplies. It also helped J&J operate as a collection of focused businesses rather than a single centralized product company.
Several major operating units took shape under that philosophy. The surgical packs and gowns business became Surgikos. The sanitary napkin operation evolved into Personal Products Company. Birth control products were handled through Ortho Pharmaceutical. The suture business became Ethicon.
The decentralized structure became one of J&J’s signatures. It helped the company grow quickly, gave managers room to adapt, and supported acquisitions by allowing new businesses to keep some independence. But it also created a problem that would surface later: a sprawling company can become inefficient when too many units operate on their own.
Johnson also promoted a formal statement of corporate responsibilities in the 1940s, commonly associated with the company’s credo. Rather than reproduce broad corporate claims as settled fact, the important business point is that J&J framed its responsibilities as extending beyond shareholders to customers, employees, communities, and then stockholders. That order became part of the company’s identity and would later be tested during major product crises.
J&J became publicly traded in 1944, listing on the New York Stock Exchange. The move marked a shift from family-controlled company to public corporation, while the Johnson family’s influence and management philosophy continued to shape the business.
Pharmaceuticals Change the Scale of the Company
Johnson & Johnson’s pharmaceutical expansion accelerated in the late 1950s and early 1960s. In 1959, the company acquired McNeil Laboratories, the maker of Tylenol, which at the time was a prescription acetaminophen pain reliever. A year later, McNeil launched Tylenol as an over-the-counter medicine.
That acquisition became one of the most consequential deals in J&J history. Tylenol eventually turned into the company’s top-selling consumer product and a centerpiece of its over-the-counter health business.
J&J also expanded in prescription drugs. The company bought Swiss pharmaceutical firm Cilag-Chemie in 1959 and Janssen Pharmaceutica in 1961. Janssen was associated with Haldol, an antipsychotic introduced in the late 1950s, and would become one of J&J’s most important pharmaceutical businesses.
The company’s growing pharma operation sat alongside its professional medical and consumer products businesses. That balance became a central part of J&J’s appeal to investors: if one category slowed, another could help carry the company. No single product was supposed to define the entire business.
Philip Hofmann became chairman in 1963 after Robert Wood Johnson II retired from the role. Hofmann continued the decentralization strategy and supported local expertise in international markets. Rather than run foreign operations only by geography, J&J organized many of them around product lines and technical knowledge.
That approach fit the company’s expanding mix. A manager selling surgical tools, baby products, or pharmaceuticals needed different expertise. J&J’s structure gave those businesses room to operate with their own commercial logic.
Consumer Marketing Turns Tylenol Into a Powerhouse
The late 1960s and 1970s brought a more aggressive consumer marketing era. James Burke, who had worked at Procter & Gamble before joining J&J, became a key figure in that shift. As federal healthcare regulation increased, J&J looked for ways to strengthen consumer products and protect profitability across the company.
Burke recruited marketing talent and pushed more visible advertising campaigns. Feminine hygiene products were one example. Carefree and Stayfree entered a market long dominated by Kimberly-Clark, and J&J took a more direct advertising approach than the category had typically used. Television advertising helped change how those products were marketed.
Tylenol became the bigger story. After Bristol-Myers introduced Datril as a lower-priced acetaminophen competitor, J&J chose to meet the challenge directly. The company cut Tylenol’s price, expanded mass-market advertising, and repositioned the brand against both Datril and older pain relievers such as Anacin.
That decision helped turn Tylenol into J&J’s leading product. It also showed how the company could combine pharmaceutical credibility with consumer-package-goods tactics. Tylenol was not just a drug on a shelf; it became a brand with national awareness and a premium reputation.
At the same time, J&J continued investing in professional healthcare. In 1977, it acquired Extracorporeal Medical Specialties, which made kidney dialysis and intravenous treatment products. In 1980, it bought Iolab, entering eye care and ophthalmic pharmaceuticals. In 1981, it acquired Frontier Contact Lenses, later renamed Vistakon.
The company also created Critikon in 1979 to support critical care products and formed Johnson & Johnson Hospital Services in 1983 to build corporate marketing programs for healthcare providers. The broader pattern was clear: consumer brands brought public visibility, but professional products and medical technology remained core to the company’s growth.
The Tylenol Crisis Became a Defining Test
In September 1982, seven people died after taking Tylenol capsules that had been laced with cyanide. The deaths created one of the most closely watched corporate crises in modern business history.
J&J canceled advertising and recalled Tylenol products from store shelves. Investigators determined that the tampering occurred at the retail level rather than during manufacturing. Still, the company had to deal with the central problem: its most important product had become associated with a fatal public health emergency.
The financial impact was immediate. J&J’s stock fell sharply in the week after the deaths, and competitors’ pain relievers gained demand as consumers avoided Tylenol. The crisis threatened not just one product line but the broader trust that J&J had spent decades building.
The company tried to recover by communicating directly, offering exchanges and refunds, and encouraging consumers to use Tylenol tablets instead of capsules. It also used coupons to bring customers back once the product returned to shelves.
The packaging response became the most lasting change. After federal regulators issued tamper-resistant packaging guidelines for food and drug products, J&J brought Tylenol back with multiple layers of protection. That move helped establish new expectations for over-the-counter medicine packaging across the industry.
Tylenol recovered much of its market position over time. By the late 1980s, it had again become a major pain-relief brand, and J&J extended the line into cold remedies and nighttime products. The company’s handling of the crisis became a case study in corporate response, though the underlying event remained a tragedy with long-running legal consequences.
Deals, Diagnostics, and Contact Lenses
The second half of the 1980s and the 1990s were defined by acquisitions and category expansion. J&J bought LifeScan in 1986, adding at-home blood-monitoring products for people with diabetes. The same year, it acquired Germany’s Penaten, strengthening its baby-care position.
Vistakon became another major success. After J&J acquired Frontier Contact Lenses, the business introduced Acuvue disposable contact lenses in the United States in 1988. Disposable contacts became a major growth category, and Acuvue helped push J&J into a leading position in vision care.
In 1989, Johnson & Johnson and Merck formed a joint venture to develop over-the-counter versions of Merck prescription medicines. The venture helped create consumer versions of products such as Mylanta and later Pepcid AC.
Leadership changed in 1989 as James Burke and David Clare retired. Ralph S. Larsen became chairman and CEO, with Robert E. Campbell and Robert N. Wilson taking senior leadership roles tied to J&J’s professional and pharmaceutical businesses.
Larsen moved to address inefficiencies created by decades of decentralization. In 1989, the infant products division was combined with health and dental units to create a broader consumer products segment, with roughly 300 jobs eliminated. J&J also consolidated professional operating departments in Europe, reducing overlap among units.
That reorganization showed the tradeoff built into J&J’s structure. Decentralization had helped the company diversify and innovate, but the cost was complexity. By the 1990s, J&J needed both local autonomy and tighter coordination.
The 1990s Acquisition Run
After slower growth in the early 1990s, Johnson & Johnson used acquisitions to accelerate expansion. The company bought RoC S.A. of France in 1993, adding hypoallergenic skin care products. In 1994, it acquired Neutrogena for nearly $1 billion, giving J&J a major dermatologist-backed consumer skin and hair care brand.
J&J also spent about $1 billion in 1995 to acquire Eastman Kodak’s clinical diagnostics unit. The business strengthened J&J in clinical chemistry and immuno-diagnostics. In 1997, the company combined that acquisition with Ortho Diagnostics Systems to create Ortho-Clinical Diagnostics.
Medical devices were another major target. Ethicon Endo-Surgery, formed in 1992, focused on endoscopic and minimally invasive surgical instruments. J&J acquired Indigo Medical in 1996, adding minimally invasive technology for urology and related areas. In 1997, it bought Biopsys Medical, which specialized in minimally invasive breast biopsies.
The biggest device move of the period was Cordis. J&J acquired Cordis in 1996 for about $1.8 billion, gaining a major business in cardiovascular products such as stents, balloons, and catheters.
In 1998, J&J made an even larger acquisition, buying DePuy for $3.7 billion in cash. DePuy was a leader in orthopedic products, including hip replacement devices, and fit with J&J’s existing strength in knee replacement.
The acquisition strategy broadened the company’s reach, but not every business was moving smoothly. J&J had been an early leader in coronary stents, but sales fell after competitors introduced newer products. The pharmaceutical pipeline also faced setbacks in the late 1990s, with multiple drugs failing in testing, being delayed, or failing to win approval.
In late 1998, J&J announced a restructuring that included cutting 4,100 jobs and closing 36 plants over the following 18 months. The company took significant charges tied to restructuring and research and development, aiming to save hundreds of millions of dollars annually.
Biotech Becomes a Bigger Bet
J&J’s push into biotechnology became more visible in 1999 with its merger with Centocor in a $4.9 billion stock-for-stock deal. It was the company’s largest transaction of that kind at the time and its first major pharmaceutical deal since the Janssen acquisition decades earlier.
Centocor strengthened J&J’s position in biotech alongside Ortho Biotech. The company gained Remicade, which received approval for rheumatoid arthritis after the merger was completed, as well as development programs in cancer, autoimmune disease, and cardiology.
The same year, J&J acquired the dermatological skin care business of S.C. Johnson & Son, including the Aveeno brand. That purchase added another consumer skin-care name to a portfolio that already included Neutrogena and RoC.
By 1999, J&J reported record results, with earnings and sales that had grown substantially over the previous decade. The company had become a rare business with scale in prescription drugs, consumer health, medical devices, diagnostics, and biotechnology.
The next year brought another reminder of the risks in healthcare. In 2000, J&J withdrew the prescription heartburn drug Propulsid after it had been linked to deaths and cardiac irregularities. The drug had generated nearly $1 billion in 1999 sales. The withdrawal underscored a recurring reality for large healthcare companies: growth in medicine carries regulatory, clinical, and reputational risk.
J&J also joined other major healthcare companies in 2000 to create an internet-based purchasing exchange for healthcare providers, a sign of how the industry was beginning to experiment with online infrastructure at the height of the dot-com era.
Why the J&J Model Worked
Johnson & Johnson’s historical advantage was not one product or one market. It was the ability to build and buy businesses across healthcare while keeping many of them focused enough to compete in specialized categories.
That model produced consumer brands with broad recognition, including Band-Aid, Tylenol, Johnson’s baby products, Neutrogena, Motrin, Aveeno, Acuvue, Stayfree, o.b., Mylanta, and Pepcid AC. It also produced less visible but strategically important businesses in sutures, surgical tools, diagnostics, diabetes care, orthopedics, cardiovascular devices, and prescription medicine.
The company’s structure gave it resilience. When one product category faced pressure, others could keep growing. When a consumer brand matured, an acquisition in devices or pharmaceuticals could open a new path. When professional medical products slowed, over-the-counter brands or international units could help offset the weakness.
But the same structure created management challenges. A company made of dozens or hundreds of operating units can become hard to coordinate. J&J’s late-1980s and late-1990s restructurings reflected that problem. The company needed the entrepreneurial energy of decentralized units without letting duplication and complexity eat into performance.
The Tylenol crisis also showed that trust could be both an asset and a liability. J&J’s reputation helped it recover, but the event proved that a single product emergency could threaten the image of the whole company. Later safety issues, including Propulsid, reinforced that reputational risk is not confined to consumer goods.
A Company Built on Breadth
By the end of the period covered here, Johnson & Johnson had become a healthcare conglomerate in the fullest sense. Its operating units spanned consumer and personal care, medical devices and diagnostics, and pharmaceuticals. Its subsidiaries included names such as Ethicon, Janssen, DePuy, Cordis, LifeScan, McNeil, Neutrogena, Ortho-Clinical Diagnostics, Ortho Biotech, Vistakon, and Centocor.
That breadth explains why Johnson & Johnson history is difficult to reduce to a simple founding myth. The company began with surgical dressings, but its growth came from repeatedly moving into adjacent markets, professionalizing consumer health categories, buying technical capability, and using brand trust as a strategic asset.
The result was a company that could sell baby shampoo and biotech drugs, adhesive bandages and artificial joints, contact lenses and cancer-related therapies. That mix made J&J unusually durable. It also made the company unusually exposed to the full range of healthcare business risks, from product competition and failed drug trials to public safety crises and regulatory scrutiny.
For readers looking at Johnson & Johnson as a business case, the lesson is not simply that diversification works. The sharper point is that diversification only works when the pieces have enough credibility, scale, and operating discipline to stand on their own. J&J spent more than a century building that kind of system, one acquisition, product line, and crisis response at a time.